APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?-Reference-Cited by-同舟云学术

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Published:2018-12-11 Issue:2 Volume:13 Page:103-109
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Kanda Tatsuo,Lau George K. K.,Wei Lai,Moriyama Mitsuhiko,Yu Ming-Lung,Chuang Wang-Long,Ibrahim Alaaeldin,Lesmana Cosmas Rinaldi Adithya,Sollano Jose,Kumar Manoj,Jindal Ankur,Sharma Barjesh Chander,Hamid Saeed S.,Dokmeci A. Kadir,Mamun-Al-Mahtab ,McCaughan Geofferey W.,Wasim Jafri,Crawford Darrell H. G.,Kao Jia-Horng,Yokosuka Osamu,Sarin Shiv Kumar,Omata Masao

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-018-9915-5.pdf

Reference41 articles.

1. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548–561

2. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435

3. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325:135–148

4. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009;76:818–824

5. Fabrizi F, Dixit V, Martin P, Messa P. The evidence-based epidemiology of HCV-associated kidney disease. Int J Artif Organs 2012;35:621–628

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals;Pathogens;2024-04-19

2. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;Hepatology International;2023-01-26

3. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease;Kidney International;2022-12

4. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5;Hepatology International;2022-07-25

5. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir;Viruses;2022-02-10